Described here are three ODYSSEY Phase @ trials , FH I ( NCT@ ) , FH II ( NCT@ ) and HIGH FH ( patients with heFH and LDL-C levels @mg/dL ) ( NCT@ ) , in which alirocumab is further evaluated in the heFH population .